Overview

Study of CS-3150 in Patients With Primary Aldosteronism

Status:
Completed
Trial end date:
2017-07-20
Target enrollment:
Participant gender:
Summary
To examine antihypertensive effect and safety of CS-3150 in patients with primary aldosteronism.
Phase:
N/A
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Treatments:
Mineralocorticoid Receptor Antagonists